Biolegend, 505802, Purified anti-mouse IFN-γ Antibody, 500μg

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
500μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli-expressed, recombinant mouse IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: ELISA Capture - Quality tested CyTOF® - Verified IHC, WB - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IFN-γ recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations: Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed Lin F, et al. 2019. Sci Adv. 5:eaax1608. PubMed Liu T, et al. 2023. Cardiovasc Res. 119:1046. PubMed Bahreyni A, et al. 2023. Biomed Pharmacother. 163:114789. PubMed Bahreyni A, et al. 2023. BMC Med. 21:193. PubMed Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed Yan J, et al. 2020. Cancer Discov. 10:124. PubMed Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed Harel M, et al. 2020. J Immunol. 205:1167. PubMed Yu H, et al. 2020. Front Immunol. 11:1773. PubMed Li H, et al. 2022. Cancer Cell. 40:36. PubMed Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed Asthagiri Arunkumar G, et al. 2019. Vaccine. 37:5567. PubMed Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed Waickman AT, et al. 2017. Cytokine. 99:266. PubMed Guo R, et al. 2020. Cell Res. 30:21. PubMed Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed Wang W, et al. 2018. Cancer Cell. 34:757. PubMed Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed Yang J, et al. 2020. Front Immunol. 10:3048. PubMed de Souza RG, et al. 2021. Am J Pathol. 191:294. PubMed Flores–Santibáñez F, et al. 2018. Front Immunol. 0.520138889. PubMed Haque M, et al. 2021. Viruses. 13:. PubMed Dienz O, et al. 2020. J Immunol. 204:1521. PubMed Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed Knuschke T, et al. 2018. Front Immunol. 0.801388889. PubMed Willimsky G, et al. 2021. Elife. 10:. PubMed Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed Zhao L, et al. 2018. Nat Med. 24:1536. PubMed Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed Kamdar K, et al. 2018. J Immunol. 201:230. PubMed Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed Juneja VR, et al. 2017. J Exp Med. 214:895. PubMed Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed Tan Z, et al. 2020. Mol Ther Oncolytics. 16:302. PubMed Opejin A, et al. 2020. Cell Reports. 33(8):108424. PubMed Hsiao CC, et al. 2021. Cells. 10:. PubMed Bittner-Eddy PD, et al. 2020. Front Immunol. 11:677. PubMed Hu G, et al. 2021. Nat Commun. 12:773. PubMed Enders M, et al. 2020. J Immunol. 204:87. PubMed Chung YM, et al. 2021. J Immunother Cancer. 9:. PubMed Riggan L, et al. 2020. Cell Rep. 31:107651. PubMed Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed Huang L, et al. 2021. Dev Neurobiol. 81:736. PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed Daley D, et al. 2017. Nat Med. 23:556. PubMed Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed Kim SJ, et al. 2020. Cell Mol Immunol. 17:728. PubMed Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed Kakaradov B, et al. 2017. Nat Immunol. 18:422. PubMed Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed Ranjan K, et al. 2021. J Clin Invest. 131:. PubMed Van Dis E, et al. 2022. PLoS Pathog. 18:e1010721. PubMed Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed Ko S, et al. 2005. J Immunol. 175:3309. PubMed Xu G, et al. 2007. J Immunol. 179:5358. PubMed Dudek M, et al. 2021. Nature. 592:444. PubMed Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed Uehara H, et al. 2021. eLife. 10:00. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed Mittal D, et al. 2017. Cancer Immunol Res. 5:1098. PubMed Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed Sun Y, et al. 2021. Nat Commun. 12:5147. PubMed Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed Kaushik DK, et al. 2019. J Clin Invest. 130. PubMed García-Lozano A, et al. 2018. Front Microbiol. 9:1275. PubMed Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed Haring J, et al. 2008. J Immunol. 180:2855. PubMed Diao J, et al. 2018. J Immunol. 201:1306. PubMed Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed Lee JK, et al. 2021. Cell Mol Immunol. 18:1395. PubMed Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed Bordoloi D, et al. 2021. Genes Cancer. 12:51. PubMed Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
RRID: AB_315395 (BioLegend Cat. No. 505801) AB_315396 (BioLegend Cat. No. 505802)
Structure: Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID: 15978
UniProt: View information about IFN-gamma on UniProt.org
Clone: XMG1.2
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype: Rat IgG1, κ